November 18, 2026
Health news, explained with evidence
LIVE

New Experimental Blood Test Detects Four Major Conditions Within One Hour

🧠 AI Analysis 2 min read 👁 4

Researchers at the University of Notre Dame have developed an experimental blood screening platform capable of identifying early markers for colorectal cancer, glioblastoma, pancreatic cancer, and Alzheimer's disease in about an hour.

New Experimental Blood Test Detects Four Major Conditions Within One Hour🧠AI Analysis

Photo: Medical Xpress

Key points

  • Notre Dame researchers developed a rapid blood test for four major diseases.
  • The method achieved 90% to 99% accuracy in a blind study of 87 plasma samples.
  • The platform detects disease-specific proteins on exosomes using specialized Janus particles.

A research team led by Hsueh-Chia Chang at the University of Notre Dame has created a diagnostic platform that uses a small blood sample to screen for four severe conditions: colorectal cancer, glioblastoma, pancreatic cancer, and Alzheimer's disease. Published in Nature Biomedical Engineering, the technology relies on detecting blood-borne exosomes, which are microscopic vesicles that carry proteins serving as early indicators of illness.

During a blind evaluation using 87 plasma samples from both healthy individuals and patients diagnosed with one of the target conditions, the platform demonstrated an accuracy rate ranging from 90% to 99%. The test requires just 10 microliters of blood diluted in saline, mixed with specialized dual-sided particles called immunojanus spheres for up to an hour, and analyzed using a proprietary computer program.

While the initial results suggest high sensitivity and selectivity, experts note that the findings stem from a relatively small, early-stage blind test. Further clinical validation with larger, diverse patient populations is necessary before this technology can be widely adopted in clinical settings. Patients should consult qualified medical professionals for any health-related screening and diagnostic decisions.

What to know

  • Technology: Uses immunojanus particles to capture and signal disease-specific exosome proteins.
  • Speed and Sample: Requires 10 microliters of blood and provides results in an hour.
  • Scope: Evaluated for colorectal cancer, glioblastoma, pancreatic cancer, and Alzheimer's disease.

Source Medical Xpress — medicalxpress.com/news/2026-11-experimental-blood-deadly-diseases-hour.… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.